Tranexamic Acid in Pertrochanteric Fractures: a Retrospective Analysis of Perioperative Outcomes After Fixation with a Proximal Femoral Nail

Overview

Journal BMC Musculoskelet Disord

Publisher Biomed Central

Specialties Orthopedics
Physiology

Date 2022 Nov 3

PMID 36324129

Authors

John Hanke

Thomas Mendel

Matthias Wingert

Philipp Schenk

Markus Heinecke

Arne Wilharm

Affiliations

Soon will be listed here.

Abstract

Background: Treatment of pertrochanteric femoral fractures is often associated with significant blood loss. It has already been demonstrated that the administration of tranexamic acid (TXA) for endoprosthetic procedures reduces blood losses and leads to a decreased frequency of postoperative complications. The aim of this study is to demonstrate whether the administration of TXA as part of osteosynthesis treatment for pertrochanteric fractures using a proximal femoral nail reduces perioperative blood losses and haemorrhage-related complications.

Methods: In a two-centre retrospective cohort study, 1 g TXA i.v. was administered preoperatively to 294 patients who had suffered from pertrochanteric femoral fractures. The subjects were compared clinically to a historical control group who did not receive TXA (nonTXA). Outcomes were evaluated on the basis of perioperative blood loss, transfusion requirement, and occurrence of complications.

Results: The TXA group showed evidence of a reduction in blood loss (TXA = 0.97 ± 0.47 l; nonTXA = 1.06 ± 0.47 l; p = 0.004) and a lower frequency of transfusion (TXA = 20%; nonTXA = 31%; p = 0.032) as compared to the nonTXA group. However, evidence of this therapeutic effect could only be demonstrated at one of the centres on subgroup comparison between the two centres. At the second centre, the data did not show a significant difference. A trend could be seen towards a reduction in postoperative renal failure. No complications occurred resulting from the administration of tranexamic acid.

Conclusion: Preoperative administration of TXA does not lead to an increased rate of thromboembolic complications when applied for treatment of pertrochanteric femoral fractures. Evidence of a positive effect could be seen in principle in relation to the reduction in perioperative blood loss and the frequency of transfusion. The difference in effect between the two centres remains to be clarified: for this reason, it is possible to assume that further factors influencing the efficacy of TXA administration are at play which were not taken into account in this study.

References

Dunn C, Goa K . Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999; 57(6):1005-32. DOI: 10.2165/00003495-199957060-00017. View

Schwab P, Lavandhomme P, Yombi J, Thienpont E . Aspirin mono-therapy continuation does not result in more bleeding after knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2015; 25(8):2586-2593. DOI: 10.1007/s00167-015-3824-0. View

Halm E, Wang J, Boockvar K, Penrod J, Silberzweig S, Magaziner J . The effect of perioperative anemia on clinical and functional outcomes in patients with hip fracture. J Orthop Trauma. 2004; 18(6):369-74. PMC: 1454739. DOI: 10.1097/00005131-200407000-00007. View

Smith G, Tsang J, Molyneux S, White T . The hidden blood loss after hip fracture. Injury. 2010; 42(2):133-5. DOI: 10.1016/j.injury.2010.02.015. View

Rupp M, Walter N, Pfeifer C, Lang S, Kerschbaum M, Krutsch W . The Incidence of Fractures Among the Adult Population of Germany–an Analysis From 2009 through 2019. Dtsch Arztebl Int. 2021; 118(40):665-669. PMC: 8727861. DOI: 10.3238/arztebl.m2021.0238. View

Poeran J, Rasul R, Suzuki S, Danninger T, Mazumdar M, Opperer M . Tranexamic acid use and postoperative outcomes in patients undergoing total hip or knee arthroplasty in the United States: retrospective analysis of effectiveness and safety. BMJ. 2014; 349:g4829. PMC: 4130961. DOI: 10.1136/bmj.g4829. View

Baruah R, Borah P, Haque R . Use of tranexamic acid in dynamic hip screw plate fixation for trochanteric fractures. J Orthop Surg (Hong Kong). 2016; 24(3):379-382. DOI: 10.1177/1602400322. View

Lei J, Zhang B, Cong Y, Zhuang Y, Wei X, Fu Y . Tranexamic acid reduces hidden blood loss in the treatment of intertrochanteric fractures with PFNA: a single-center randomized controlled trial. J Orthop Surg Res. 2017; 12(1):124. PMC: 5558747. DOI: 10.1186/s13018-017-0625-9. View

Tian S, Shen Z, Liu Y, Zhang Y, Peng A . The effect of tranexamic acid on hidden bleeding in older intertrochanteric fracture patients treated with PFNA. Injury. 2018; 49(3):680-684. DOI: 10.1016/j.injury.2018.01.026. View

10.

Chen F, Jiang Z, Li M, Zhu X . Efficacy and safety of perioperative tranexamic acid in elderly patients undergoing trochanteric fracture surgery: a randomised controlled trial. Hong Kong Med J. 2019; 25(2):120-126. DOI: 10.12809/hkmj187570. View

11.

Boddaert J, Raux M, Khiami F, Riou B . Perioperative management of elderly patients with hip fracture. Anesthesiology. 2014; 121(6):1336-41. DOI: 10.1097/ALN.0000000000000478. View

12.

Vochteloo A, van der Burg B, Mertens B, Niggebrugge A, de Vries M, Tuinebreijer W . Outcome in hip fracture patients related to anemia at admission and allogeneic blood transfusion: an analysis of 1262 surgically treated patients. BMC Musculoskelet Disord. 2011; 12:262. PMC: 3226448. DOI: 10.1186/1471-2474-12-262. View

13.

Klein H, Spahn D, Carson J . Red blood cell transfusion in clinical practice. Lancet. 2007; 370(9585):415-26. DOI: 10.1016/S0140-6736(07)61197-0. View

14.

Tengberg P, Foss N, Palm H, Kallemose T, Troelsen A . Tranexamic acid reduces blood loss in patients with extracapsular fractures of the hip: results of a randomised controlled trial. Bone Joint J. 2016; 98-B(6):747-53. DOI: 10.1302/0301-620X.98B6.36645. View

15.

Schurch M, Rizzoli R, Mermillod B, VASEY H, Michel J, Bonjour J . A prospective study on socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res. 1996; 11(12):1935-42. DOI: 10.1002/jbmr.5650111215. View

16.

Foss N, Kehlet H . Hidden blood loss after surgery for hip fracture. J Bone Joint Surg Br. 2006; 88(8):1053-9. DOI: 10.1302/0301-620X.88B8.17534. View

17.

Schiavone A, Bisaccia M, Inkov I, Rinonapoli G, Manni M, Rollo G . Tranexamic Acid in Pertrochanteric Femoral Fracture: Is it a Safe Drug or Not?. Folia Med (Plovdiv). 2018; 60(1):67-78. DOI: 10.1515/folmed-2017-0070. View

18.

Roberts I, Shakur H, Afolabi A, Brohi K, Coats T, Dewan Y . The importance of early treatment with tranexamic acid in bleeding trauma patients: an exploratory analysis of the CRASH-2 randomised controlled trial. Lancet. 2011; 377(9771):1096-101, 1101.e1-2. DOI: 10.1016/S0140-6736(11)60278-X. View

19.

Alshryda S, Sarda P, Sukeik M, Nargol A, Blenkinsopp J, Mason J . Tranexamic acid in total knee replacement: a systematic review and meta-analysis. J Bone Joint Surg Br. 2011; 93(12):1577-85. DOI: 10.1302/0301-620X.93B12.26989. View

20.

Vijay B, Bedi V, Mitra S, Das B . Role of tranexamic acid in reducing postoperative blood loss and transfusion requirement in patients undergoing hip and femoral surgeries. Saudi J Anaesth. 2013; 7(1):29-32. PMC: 3657919. DOI: 10.4103/1658-354X.109803. View